SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $5.70, for a total value of $28,500.00. Following the completion of the sale, the insider directly owned 228,387 shares in the company, valued at $1,301,805.90. This represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total value of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.82, for a total transaction of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total transaction of $3,161.60.

SOPHiA GENETICS Stock Down 0.7%

NASDAQ SOPH traded down $0.04 on Tuesday, hitting $5.68. 120,863 shares of the stock were exchanged, compared to its average volume of 190,422. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.30. The company has a market cap of $476.50 million, a PE ratio of -10.92 and a beta of 0.96. The company has a 50-day moving average price of $5.18 and a 200-day moving average price of $4.99.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. 1492 Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $973,000. Royce & Associates LP purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $2,009,000. Hodges Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the 1st quarter worth $2,157,000. Royal Bank of Canada raised its stake in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS in the second quarter valued at $567,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.